Insulin glargine, a long-acting insulin analog, is essential in managing diabetes, providing steady glucose control over 24 hours. As diabetes cases continue to rise globally, biosimilars of insulin glargine have emerged as affordable alternatives to branded products like Sanofi’s Lantus, reducing the financial burden on healthcare systems and patients alike. Market Outlook for Insulin...

The global pain management devices market is estimated to grow from $7.94 billion in 2024 to $13.32 billion by 2035, at a CAGR of 4.8% during the forecast period, till 2035. During our research, we were able to identify more than 30 leading players that are engaged in the pain management devices market. Majority of the leading players (80%) engaged in pain management devices market are...